Faster HIV-1 Disease Progression among Brazilian Individuals Recently Infected with CXCR4-Utilizing Strains

Carregando...
Imagem de Miniatura
Citações na Scopus
29
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
SUCUPIRA, Maria Cecilia Araripe
CORTES, Rodrigo M.
TOMIYAMA, Helena
SAUER, Mariana M.
JANINI, Luiz Mario
DIAZ, Ricardo Sobhie
Citação
PLOS ONE, v.7, n.1, article ID e30292, 9p, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Primary HIV infection is usually caused by R5 viruses, and there is an association between the emergence of CCXR4-utilizing strains and faster disease progression. We characterized HIV-1 from a cohort of recently infected individuals in Brazil, predicted the virus's co-receptor use based on the env genotype and attempted to correlate virus profiles with disease progression. Methods: A total of 72 recently infected HIV patients were recruited based on the Serologic Testing Algorithm for Recent HIV Seroconversion and were followed every three to four months for up to 78 weeks. The HIV-1 V3 region was characterized by sequencing nine to twelve weeks after enrollment. Disease progression was characterized by CD4+ T-cell count decline to levels consistently below 350 cells/mu L. Results: Twelve out of 72 individuals (17%) were predicted to harbor CXCR4-utilizing strains; a baseline CD4,350 was more frequent among these individuals (p = 0.03). Fifty-seven individuals that were predicted to have CCR5-utilizing viruses and 10 individuals having CXCR4-utilizing strains presented with baseline CD4.350; after 78 weeks, 33 individuals with CCR5 strains and one individual with CXCR4 strains had CD4.350 (p = 0.001). There was no association between CD4 decline and demographic characteristics or HIV-1 subtype. Conclusions: Our findings confirm the presence of strains with higher in vitro pathogenicity during early HIV infection, suggesting that even among recently infected individuals, rapid progression may be a consequence of the early emergence of CXCR4-utilizing strains. Characterizing the HIV-1 V3 region by sequencing may be useful in predicting disease progression and guiding treatment initiation decisions.
Palavras-chave
Referências
  1. Accetturi CA, 2000, J ACQ IMMUN DEF SYND, V24, P399
  2. Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724
  3. Brenner BG, 2008, AIDS, V22, P2509, DOI 10.1097/QAD.0b013e3283121c90
  4. Busch MP, 2010, AIDS, V24, P2763, DOI 10.1097/QAD.0b013e32833f1142
  5. Casseb J, 2002, INT J INFECT DIS, V6, P164
  6. Cavaleiro R, 2007, EUR J IMMUNOL, V37, P3435, DOI 10.1002/eji.200737511
  7. Cecilia D, 2000, VIROLOGY, V271, P253, DOI 10.1006/viro.2000.0297
  8. Cimerman S, 2007, AIDS PATIENT CARE ST, V21, P100, DOI 10.1089/apc.2006.0035
  9. Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
  10. de Mendoza C, 2008, JAIDS-J ACQ IMM DEF, V48, P241, DOI 10.1097/QAI.0b013e3181734f0e
  11. Diaz RS, 1997, AIDS, V11, P415, DOI 10.1097/00002030-199704000-00003
  12. Diaz RS, 1996, AIDS RES HUM RETROV, V12, P1291, DOI 10.1089/aid.1996.12.1291
  13. Diaz RS, 2008, SELECTIVE R IN PRESS
  14. Easterbrook PJ, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-4
  15. Frange P, 2009, J ANTIMICROB CHEMOTH, V64, P135, DOI 10.1093/jac/dkp151
  16. Fusuma EE, 2005, AIDS RES HUM RETROV, V21, P965, DOI 10.1089/aid.2005.21.965
  17. Hendel H, 1999, J IMMUNOL, V162, P6942
  18. Huang W, 2009, AIDS RES HUM RETROV, V25, P795, DOI 10.1089/aid.2008.0252
  19. Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143
  20. Ioannidis JPA, 2001, ANN INTERN MED, V135, P782
  21. Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
  22. Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X
  23. Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
  24. Kanki PJ, 1999, J INFECT DIS, V179, P68, DOI 10.1086/314557
  25. Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105
  26. KOOT M, 1993, ANN INTERN MED, V118, P681
  27. Kothe D, 2003, JAIDS-J ACQ IMM DEF, V33, P625, DOI 10.1097/00126334-200308150-00012
  28. Leal, 2008, RETROVIROLOGY RES TR, V2008, P1
  29. Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
  30. Markowitz M, 2005, LANCET, V365, P1031
  31. McGovern RA, 2010, AIDS, V24, P2512, DOI 10.1097/QAD.0b013e32833e6cfb
  32. Mellors JW, 2007, JAMA-J AM MED ASSOC, V297, P2349, DOI 10.1001/jama.297.21.2349
  33. Montano MA, 1997, J VIROL, V71, P8657
  34. Munerato Patrícia, 2003, Braz J Infect Dis, V7, P236, DOI 10.1590/S1413-86702003000400002
  35. Ping LH, 1999, J VIROL, V73, P6271
  36. Raymond S, 2010, AIDS, V24, P2305, DOI 10.1097/QAD.0b013e32833e50bb
  37. Sanabani S, 2006, AIDS RES HUM RETROV, V22, P171, DOI 10.1089/aid.2006.22.171
  38. Santoro-Lopes G, 2000, AIDS RES HUM RETROV, V16, P953, DOI 10.1089/08892220050058362
  39. Schlueter V, 1996, J CLIN MICROBIOL, V34, P2660
  40. Sing T, 2007, ANTIVIR THER, V12, P1097
  41. Souza IE, 2006, HIV MED, V7, P25, DOI 10.1111/j.1468-1293.2005.00339.x
  42. Sucupira MCA, 2007, AIDS PATIENT CARE ST, V21, P116, DOI 10.1089/apc.2006.0079
  43. Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
  44. Tscherning C, 1998, VIROLOGY, V241, P181, DOI 10.1006/viro.1997.8980
  45. Tucker TJ, 1999, J MED VIROL, V59, P52, DOI 10.1002/(SICI)1096-9071(199909)59:1<52::AID-JMV9>3.0.CO;2-D
  46. Verhofstede C, 2009, JAIDS-J ACQ IMM DEF, V50, P126, DOI 10.1097/QAI.0b013e31819118fa
  47. Westby M, 2007, J VIROL, V81, P2359, DOI 10.1128/JVI.02006-06
  48. Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389
  49. Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364